Positions

Professor
Urology
Baylor College of Medicine
Houston, TX, US
Beth and Dave Swalm Chair in Urologic Oncology
Director of Urologic Oncology
Director of the Multidisciplinary Bladder Cancer Program

Education

B.A. from University Of Texas At Austin
M.D. from Baylor College Of Medicine
Internship at Virginia Mason Hospital
Residency at Virginia Mason Hospital
General Surgery
Residency at Baylor College of Medicine
Urology
Fellowship at University Of Southern California
Urologic Oncology

Certifications

American Board of Urology

Professional Interests

  • Urologic Oncology and Reconstructive Surgery with Interest in Minimally Invasive Surgery

Professional Statement

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic.

He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer.

Dr. Lerner is author of over190 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. He is the founding co-editor-in-chief of the Bladder Cancer journal. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated genomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 26 years experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force and current co-chair of the NCI CTEP Genitourinary Steering Committee, and he has co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer for the past 7 years. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America.

Selected Publications

Memberships

American Association of Genitourinary Surgeons
American Urological Association
American Association for Cancer Research
American Association for the Advancement of Science
American College of Surgeons
American Medical Association
American Society of Clinical Oncology
American Society of Gene Therapy
American Association of Clinical Urologists
Harris County Medical Society
International Bladder Cancer Network
Society of Basic Urologic Research
Société International D’Urologie
Society of Laparoendoscopic Surgeons
South Central Section of the American Urological Association
Society of University Urologists
Southwest Oncology Group
Texas Urological Society
Texas Medical Association

Skills

Research Interests
Bladder Cancer Collaborative Research Program: Role of estrogen receptors and the use of selective estrogen receptor modulators (e.g., tamoxifen) for treatment of bladder cancer; novel targeted therapeutics and gene therapy for treatment of non-muscle-invasive and invasive disease; outcome of treatments for non-muscle-invasive bladder cancer and radical cystectomy and development of predictive models; genomic characterization and integrated analysis of bladder and upper tract cancers
Clinical Interests
Urologic oncology and urinary tract reconstruction; management of patients with bladder, prostate, testis and kidney cancer; Director, Bladder Cancer Multidisciplinary Clinical Program
Clinical Trials
Bladder cancer; prostate cancer; kidney cancer